Open AccessJPH203 as a potential L-Type Amino Acid Transporter 1 (LAT 1) inhibitor in the development of cancer theragnostic compounds
Author(s) -
Yolanda Pertiwi,
Driyanti Rahayu,
Maula Eka Sriyani,
Raden Bayu Indradi,
Holis Abdul Holik
Publication year - 2020
Publication title -
jurnal ilmiah farmasi
Language(s) - English
Resource type - Journals
ISSN - 1693-8666
DOI - 10.20885/jif.vol16.iss2.art8
Subject(s) - cancer cell , cancer , cancer therapy , transporter , cancer research , pharmacology , amino acid transporter , amino acid , chemistry , medicine , computational biology , biochemistry , biology , gene
Background: Cancer has become a major cause of global health problems. Latest research currently focuses on an approach to cancer therapy that involves specific target molecules and theragnostic (therapy and diagnostic) agents. Among the specific target molecules in cancer therapy is LAT1, which is over expressed in cancer cells but under expressed in normal cells. Therefore, LAT1 inhibition can become an alternative to cancer therapy. A number of studies have shown that JPH203 specifically inhibits LAT1, thus reducing amino acid absorption into cancer cells and inhibiting cancer cell growth. Objective: The main objective of this literature study was to determine the potential of JPH203 as a LAT1 inhibitor to be developed into a novel theragnostic agent for cancer. Methods: Various studies were summarized to outline the development of JPH203 as a therapy targeting LAT1 and potential candidate of theragnostic compounds. Results: The results of the literature study showed that JPH203 as a selective LAT1 inhibitor was able to efficiently suppress the growth of cancer cells with a low IC50 value. Conclusion: The activity of LAT1 as an amino acid transporter of cancer cells could be selectively inhibited by JPH203, thereby allowing JPH203 to be reconsidered as a potential therapy in the development of theragnostic compounds against cancer. Keywords: JPH203, theragnostic, LAT1 inhibitor